Phase II single arm open pilot study to demonstrate the efficacy of midostaurin in symptom improvement and decrease of mast cell burden in patients with indolent or smoldering systemic mastocytosis - Midostaurin in Indolent Systemic Mastocytosis

niversitair Medisch Centrum Groningen0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•* Patients with ISM or SSM according to the WHO criteria
•* Presence of the D816V c-KIT mutation
•* Serum tryptase > 20 mg/l
•* Serious mediator-related symptoms that cannot be controlled by H1 and H2 blocking drugs. Symptoms will be scored by an adapted MSAF (mastocytosis symptom assessment form15) with at least
•o a pre-study score of 4 or more on 3 non-related items,
•o or a pre-study score of 5 or more on 2 non-related items.
•o one item from the scoring list can be replaced by flushes 7 or more per week or anaphylactic attacks 1 or more per week
•* Age >18 years
•* Willingness to apply optimal contraceptive measures (double barrier method, both men and women) if applicable, e.g. women below the age of 55, men at all ages; for both: if sexually active.
•* Written informed consent

•- Aggressive systemic mastocytosis, mast cell leukemia, or ASM with or without
•accompanying non-clonal related non-mast cell disorder (SM-ANHMD).
•* Any known other present malignancy, non-melanoma skin cancers excluded
•* History of malignancy within the last 5 years, non-melanoma skin cancers excluded
•* Any serious comorbidity interfering with therapy compliance and follow-up compliance
•* Pregnancy
•* Patients not willing or who are not able to comply with contraceptive measures

发起方